Gb Sciences is developing a first-in-class, cannabinoid-based treatment for the motor symptoms of Parkinson’s disease

[Farooqji]

Gb Sciences has completed a study testing its experimental cannabinoid-based therapy for Parkinson’s disease in rodents.

The study, which was conducted at the University of Lethbridge, in Canada, tested a range of doses of the investigational therapy, establishing how long it takes each dose to have an effect and how long the effect lasts. Results also suggested the therapy was generally well tolerated, with no safety issues reported.

Buoyed by the data, Gb is planning to file an investigational new drug application — a formal request to the U.S. Food and Drug Administration (FDA) asking for permission to begin clinical testing in humans — as early as next year.

parkinsonsnewstoday.com/new...